LLY vs PFE
LLY and PFE side by side — valuation & fundamentals (public data).
Key statistics
| Metric | LLYELI LILLY & Co | PFEPfizer Inc. |
|---|---|---|
| Market cap | $1.11T | $142.77B |
| P/E (TTM) | 41.9 | 19.1 |
| P/B | 35.58 | 1.58 |
| P/S | 17.0x | 2.3x |
| Dividend yield | — | 6.84% |
| Revenue | $72.25B(TTM) | $63.31B(TTM) |
| Revenue growth (YoY) | 44.7% | -1.6% |
| Net income | $25.28B(TTM) | $7.49B(TTM) |
| Earnings growth (YoY) | 94.9% | -3.2% |
| EPS, diluted | $28.15(TTM) | $1.31(TTM) |
| EBIT margin | 40.2% | 16.3% |
| ROE | 66.2% | 8.6% |
| ROIC | 30.4% | 6.7% |
| 1y total return | +55.5% | +8.8% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: LLY frente a PFE
| Métrica | LLY | PFE |
|---|---|---|
| Valor final | $195.8K | $13.4K |
| Retorno total | +1858.0% | +33.5% |
| CAGR | +33.3% | +2.8% |
| Volatilidad | 30.0% | 23.9% |
| Sharpe | 0.98 | 0.08 |
| Sortino | 1.53 | 0.11 |
| Caída máxima | -34.5% | -59.0% |
Basado en 2600 días de negociación comunes, 2016-03-15 → 2026-07-17 · tasa libre de riesgo 3.85% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)